Strategy analysis

May 28, 2019

2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report

June 13, 2019

When Deals Go Wrong: Lessons from Failure

July 12, 2019

Early Access to Medicines in the US and Europe

July 15, 2019

2019 Post-ADA Report

July 22, 2019

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

Immuno-oncology continues to draw pharma companies to the deal table.

August 5, 2019

Big Pharma Licensing Trends, 2014–18

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

August 20, 2019

Spotlight on Antibody-Drug Conjugates

The first antibody-drug conjugate (ADC), Mylotarg, reached the market almost two decades ago. Since this time, the ADC field has undergone slow but transformative enhancements, with improvements to technologies and advancements in the pipeline leading to an invigoration of the field. The past couple of years have seen the approvals of three new ADCs: Polivy, Lumoxiti, and Besponsa, increasing the total number of ADCs approved by regulators worldwide to six. These approvals mark the start of a new era in which the ADC field is finally beginning to realize its full potential. With the ADC pipeline swelling to around 250 novel candidates in various stages of preclinical and clinical development, approvals for more ADCs appear firmly on the horizon.

September 20, 2019

Biosimilars in the US and Europe

Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents.

June 25, 2019

Key Potential Drug Launches in 2021

July 24, 2020

Datamonitor Big Pharma Licensing Trends

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Mid Pharma Outlook

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

September 28, 2016

Innovation in Deal-Making

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.

June 13, 2018

Market Access Trends in Europe

Health technology assessments (HTAs) have become an integral part of procedures employed to inform new drug coverage and pricing decisions across Europe. Methodological approaches to HTA vary, however, while disparities are also apparent in the pertise and financial resources to conduct multidisciplinary assessments, and in the relative weight accorded to recommendations issued by national (or regional) HTA agencies (ICOM, 2017)

November 16, 2018

Access Trends in Emerging Markets

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.

February 20, 2019